26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 5: coronary artery disease.
作者信息
Thompson P D, Klocke F J, Levine B D, Van Camp S P
出版信息
Med Sci Sports Exerc. 1994 Oct;26(10 Suppl):S271-5.
PMID:7934751
Abstract
摘要
相似文献
1
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 5: coronary artery disease.
Med Sci Sports Exerc. 1994 Oct;26(10 Suppl):S271-5.
2
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 5: coronary artery disease.
J Am Coll Cardiol. 1994 Oct;24(4):888-92. doi: 10.1016/0735-1097(94)90846-x.
3
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 1: congenital heart disease.
Med Sci Sports Exerc. 1994 Oct;26(10 Suppl):S246-53.
4
5
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 6: arrhythmias.第26届贝塞斯达会议：关于确定心血管异常运动员参赛资格的建议。第6工作组：心律失常
Med Sci Sports Exerc. 1994 Oct;26(10 Suppl):S276-83.
6
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse.第26届贝塞斯达会议：关于确定心血管异常运动员参赛资格的建议。第3工作组：肥厚型心肌病、心肌炎及其他心肌心包疾病和二尖瓣脱垂。
Med Sci Sports Exerc. 1994 Oct;26(10 Suppl):S261-7.
7
8
Cardiovascular disease in athletes.运动员的心血管疾病
Clin Sports Med. 2004 Jul;23(3):455-71, x. doi: 10.1016/j.csm.2004.02.002.
9
Legal considerations that affect medical eligibility for competitive athletes with cardiovascular abnormalities and acceptance of Bethesda Conference recommendations.
Med Sci Sports Exerc. 1994 Oct;26(10 Suppl):S238-41.
10
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 4: systemic hypertension.第26届贝塞斯达会议：关于确定心血管异常运动员参赛资格的建议。第4工作组：系统性高血压。
J Am Coll Cardiol. 1994 Oct;24(4):885-8. doi: 10.1016/0735-1097(94)90845-1.
引用本文的文献
1
Platelet hyperactivity during exercise leading to iterative coronary stent thrombosis: clinical implications.运动期间血小板活性增高导致冠状动脉支架内血栓形成的反复发作：临床意义。
J Thromb Thrombolysis. 2010 Jul;30(1):105-8. doi: 10.1007/s11239-009-0394-3.
Zotero 插件